🇺🇸 FDA
Pipeline program

Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK

AT-01B-006

Phase 1 small_molecule completed

Quick answer

Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK for Healthy Volunteer Study is a Phase 1 program (small_molecule) at Atea Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Atea Pharmaceuticals
Indication
Healthy Volunteer Study
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials